1 / 15

Tackling DDW

The role of the pharmaceutical R&D based industry in addressing diseases of the developing world (DDW).

Download Presentation

Tackling DDW

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The role of the pharmaceutical R&D based industry in addressing diseases of the developing world (DDW) Jon D. PenderVice President, IP & Access, Global Health Government Affairs, Public Policy and Patient Advocacy, GSKChair, Global Health Committee, IFPMACEWG Open Forum | Geneva | 6 April 2011

  2. Tackling DDW a combined effort to benefit patients in developing countries

  3. Industry commits resources to R&D R&D for DDW is conducted through multiple channels Independent efforts Partnerships/academia Dedicated R&D facilities *(Current industry involvement & partnerships - illustrative only - not comprehensive)

  4. R&D for a New Medicine

  5. Industry R&D for DDW is Growing… # R&D Projects by IFPMA Companies, with Product Development Partnerships or alone • R&D for TDR 10 Priority Diseases: • Chagas- Dengue- Human African Trypanosomiasis- Leishmaniasis- Leprosy- Lymphatic Filariasis- Malaria- Onchocerciasis- Schistosomiasis- Tuberculosis • 1 project = 1 compound in development OR 1 screening programme for 1 disease • Source: 2005, Moran et al. “New Landscape...”; 2006-10, IFPMA Status Report

  6. ...and increasingly collaborative # Medicines and Vaccines R&D Projects with Product Development Partnerships or alone

  7. Factors for Increased DDW R&D

  8. Current Industry DDW R&D is Mostly Early Stage

  9. Some DDWs are More Neglected than Others 4 Approved Meds: ALL intravenous or intramuscular, 3 are v. old 0 Approved Meds 2 Approved Meds: 1) intravenous & side effects 2) v. expensive 2 Approved Meds: BOTH less effective against fatal late stage 1 Approved Med: Effective, large donation program. Resistance? 3 Approved Meds: Effective, large donation program 3 Approved Meds: Effective, large donation program 1 Approved Med: Effective, large donation program (HAT = Human African Trypanosomiasis or “Sleeping Sickness”) Source: 2010 IFPMA Status Report

  10. Funding for R&D for DDW is Growing…

  11. ….But a Funding Crisis is Looming DalbergStudy for IFPMA (2007) • Total Funding for PDPs to 2007 = USD 0.5 billion • Est. funding to take current PDP pipelines to approval AND to augment inadequate pipelines for Most Neglected Diseases = USD 8.3 billion Source: Dalberg for IFPMA 11

  12. DDW R&D Trends that will Impact Financing

  13. Summary • DDW R&D has increased substantially • Increased activity by Product Development Partnerships • Increased investment, in-kind & not-for-profit contribution by industry • Current DDW R&D is mainly in less expensive earlier stages • Funding requirements will increase as more projects move into clinical trials • Industry is working to help expand and improve current DDW efforts • Current volume of DDW R&D inadequate to deliver enough new medicines for all the most needy diseases • Shortfall is significant – funding to date perhaps 10 % of what is needed • Additional funding critical to achieve adequate range of new medicines & vaccines for the Most Neglected Diseases

  14. Conclusions • R&D Industry welcomes new sustainable proposals that complement the current innovation system • IFPMA committed to the implementation of the relevant provisions of the GSPoA • Pools • Tech transfer • Factors for new successful proposals: • able to be implemented in the short to medium-term • sufficiently credible to engage key funding sources • endorsed by key providers of research and development • demonstrably non-erosive of existing efforts

  15. Thank You!

More Related